The multibiomarker disease activity (MBDA) scale appears to be a very versatile tool, based on results presented at the 2015 annual meeting of the American College of Rheumatology.
Clinicians may be able to use the multibiomarker disease activity (MBDA) score to predict rheumatoid arthritis (RA) flares within a year of discontinuation of tumor necrosis factor inhibitor (TNFi).
New criteria for diagnosing and classifying gout are helping not only researchers but also those working at the bedside.
The versatile multibiomarker disease activity (MBDA) score may be able to predict rheumatoid arthritis (RA) relapse within the first year of tapering disease-modifying antirheumatic drug (DMARD) treatment.
Although no biosimilar copy of a biologic therapy specific to rheumatoid arthritis (RA) has been approved by the US Food and Drug Administration, studies continue to be encouraging.
For patients withrheumatoid arthritis (RA) who do not have an adequate response to anti–tumor necrosis factor (anti-TNF) therapy, switching to another anti-TNF appears to be the wiser choice from both a health and an economic standpoint.
Chondroitin sulfate was superior to celecoxib in reducing the progression of long-term damage of knee osteoarthritis (OA) in the first randomized trial to demonstrate this. Chondroitin sulfate was safe over a 2-year period, with no significant side effects.
Intra-articular (IA) corticosteroid (CS) injections do not prevent long-term structural damage in patients with knee osteoarthritis (OA), nor do the injections hasten joint damage, according to the results of a National Institutes of Health–funded randomized clinical trial.
Exercise is beneficial for patients with knee osteoarthritis (OA), but few studies have addressed which is the most beneficial and cost-effective strategy.
The American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) have produced a set of recommendations and an algorithm for the management of polymyalgia rheumatica (PMR).
Page 3 of 4
Results 21 - 30 of 33
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology